                         SEQUENCE LISTING

<110>  Tel HaShomer Medical Research Infrastructure and Services 
       Ltd.
       CHAPMAN, Joab
       SHAVIT STEIN, Efrat
       ROTENSTREICH, Ygal
       SHER, Ifat
 
<120>  TREATMENT OF RETINAL DEGENERATION

<130>  90031

<150>  US 63/111,151
<151>  2020-11-09

<160>  17    

<170>  PatentIn version 3.5

<210>  1
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide moiety (P)  of Formula I

<400>  1

Leu Asp Pro Arg 
1               


<210>  2
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide moiety (P)  of Formula I

<400>  2

Thr Leu Asp Pro Arg 
1               5   


<210>  3
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide moiety (P)  of Formula I

<400>  3

Ala Thr Leu Asp Pro Arg 
1               5       


<210>  4
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide moiety (P)  of Formula I

<400>  4

Asn Ala Thr Leu Asp Pro Arg 
1               5           


<210>  5
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide moiety (P)  of Formula I

<400>  5

Thr Asn Ala Thr Leu Asp Pro Arg 
1               5               


<210>  6
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide moiety (P)  of Formula I

<400>  6

Ala Thr Asn Ala Thr Leu Asp Pro Arg 
1               5                   


<210>  7
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide moiety (P)  of Formula I

<400>  7

Lys Ala Thr Asn Ala Thr Leu Asp Pro Arg 
1               5                   10  


<210>  8
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide moiety (P)  of Formula I

<400>  8

Ser Lys Ala Thr Asn Ala Thr Leu Asp Pro Arg 
1               5                   10      


<210>  9
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide moiety (P)  of Formula I

<400>  9

Glu Ser Lys Ala Thr Asn Ala Thr Leu Asp Pro Arg 
1               5                   10          


<210>  10
<211>  13
<212>  PRT
<213>  Artificial sequence

<220>
<223>  thrombin-recognition site in PAR-1

<400>  10

Pro Glu Ser Lys Ala Thr Asn Ala Thr Leu Asp Pro Arg 
1               5                   10              


<210>  11
<211>  14
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide moiety (P)  of Formula I

<400>  11

Arg Pro Glu Ser Lys Ala Thr Asn Ala Thr Leu Asp Pro Arg 
1               5                   10                  


<210>  12
<211>  15
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide moiety (P)  of Formula I

<400>  12

Arg Arg Pro Glu Ser Lys Ala Thr Asn Ala Thr Leu Asp Pro Arg 
1               5                   10                  15  


<210>  13
<211>  16
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide moiety (P)  of Formula I

<400>  13

Ala Arg Arg Pro Glu Ser Lys Ala Thr Asn Ala Thr Leu Asp Pro Arg 
1               5                   10                  15      


<210>  14
<211>  17
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide moiety (P)  of Formula I

<400>  14

Arg Ala Arg Arg Pro Glu Ser Lys Ala Thr Asn Ala Thr Leu Asp Pro 
1               5                   10                  15      


Arg 
    


<210>  15
<211>  18
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide moiety (P)  of Formula I

<400>  15

Thr Arg Ala Arg Arg Pro Glu Ser Lys Ala Thr Asn Ala Thr Leu Asp 
1               5                   10                  15      


Pro Arg 
        


<210>  16
<211>  19
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide moiety (P)  of Formula I

<400>  16

Arg Thr Arg Ala Arg Arg Pro Glu Ser Lys Ala Thr Asn Ala Thr Leu 
1               5                   10                  15      


Asp Pro Arg 
            


<210>  17
<211>  20
<212>  PRT
<213>  Artificial sequence

<220>
<223>  peptide moiety (P)  of Formula I

<400>  17

Ala Arg Thr Arg Ala Arg Arg Pro Glu Ser Lys Ala Thr Asn Ala Thr 
1               5                   10                  15      


Leu Asp Pro Arg 
            20  


